Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2007-12-04
2007-12-04
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C514S220000
Reexamination Certificate
active
10613619
ABSTRACT:
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
REFERENCES:
patent: 3354036 (1967-11-01), Jelinek
patent: 3676557 (1972-07-01), Lachman et al.
patent: 3904670 (1975-09-01), Ricard et al.
patent: 3956330 (1976-05-01), Corey, Jr. et al.
patent: 4016273 (1977-04-01), Sieger et al.
patent: 4076942 (1978-02-01), Smith et al.
patent: 4320124 (1982-03-01), Koe
patent: H672 (1989-09-01), Baxter et al.
patent: 4977150 (1990-12-01), Chakrabarti et al.
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5292760 (1994-03-01), Martin et al.
patent: 5439688 (1995-08-01), Orsolini et al.
patent: 5605897 (1997-02-01), Beasley, Jr. et al.
patent: 5612346 (1997-03-01), Mesens et al.
patent: 5639480 (1997-06-01), Bodmer et al.
patent: 5723467 (1998-03-01), Mesens et al.
patent: 5736152 (1998-04-01), Dunn
patent: 5736541 (1998-04-01), Bunnett et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5776885 (1998-07-01), Orsolini et al.
patent: 5776928 (1998-07-01), Beasley, Jr.
patent: 6169084 (2001-01-01), Bunnett et al.
patent: 6617321 (2003-09-01), Allen et al.
patent: 0568096 (1993-11-01), None
patent: 1 539 277 (1979-01-01), None
patent: WO 96/29995 (1996-10-01), None
patent: WO 96/30375 (1996-10-01), None
patent: WO 98/11893 (1998-03-01), None
patent: WO 2006/073886 (2006-07-01), None
Second College Edition, The American Heritage Dictionary, 1976, p. 866.
Hugarian Search Report, App. No. P 00 04534, X-11666.
E. Saias et al. A class of oral retard and sustained effect drugs: the pamoates,Annales Pharmaceutiques Francaises, 1969, pp. 557-570, 27(9-10).
Harold L. Goldberg., M.D. et al, A Double-Blind Study of Tofranil Pamoate vs. Tofranil Hydrochloride,Psychosomatics, Mar.-Apr. 1972, pp. 131-134, vol. XIII.
William C. Miller, Jr. et al., A Controlled Study of Single-Dose Administration of Imipramine Pamoate in Endogenous Depression,Current Therapeutic Research, Oct. 1973, pp. 700-706, 15(10).
A. T. Florence et al., Effect of Formulation of Intramuscular Injections of Phenothiazines on Duration of Activity,Journal of Pharmaceutical Sciences, Nov. 1976, pp. 1665-1668, 65(11).
Stephen M. Berge et al., Pharmaceutical Salts,Journal of Pharmaceutical Science, Jan. 1977, pp. 1-19, 66(1).
Philip L. Gould, Salt selection for basic drugs,International Journal of Pharmaceutics, 1986, pp. 201-217, 33.
H. C. Caldwell et al., Latentiation of Dihydrostreptomycin by Pamoate Formation,Journal of Pharmaceutical Sciences, 1970, pp. 1689-1690, 59.
Allen Douglas J.
Brooks Norman D.
Bunnell Charles A.
Dekemper Kurt D.
Ferguson Thomas H.
Eli Lilly and Company
Fubara Blessing
Hartley Michael G.
Lentz Nelson L.
LandOfFree
2-methyl-thieno-benzodiazepine formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-methyl-thieno-benzodiazepine formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-methyl-thieno-benzodiazepine formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845653